MX2013010524A - Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer. - Google Patents

Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.

Info

Publication number
MX2013010524A
MX2013010524A MX2013010524A MX2013010524A MX2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A
Authority
MX
Mexico
Prior art keywords
prostate cancer
combination
mammalian subject
hsp90 inhibitor
oligonucleotide
Prior art date
Application number
MX2013010524A
Other languages
Spanish (es)
Inventor
Amina Zoubeidi
Martin E Gleave
Francois Lamoureux
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MX2013010524A publication Critical patent/MX2013010524A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

The present invention provides a method for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Heat Shock Protein 90 (Hsp90) inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject. The present invention also provides pharmaceutical compositions comprising an amount of an oligonucleotide which reduces clusterin expression, and a Hsp90 inhibitor for use in treating a mammalian subject affected by prostate cancer. Also provided are oligonucleotides which reduce clusterin expression for use in combination with a Hsp90 inhibitor in treating a mammalian subject affected by prostate cancer, and a composition for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Hsp90 inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject.
MX2013010524A 2011-03-15 2012-03-12 Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer. MX2013010524A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453102P 2011-03-15 2011-03-15
PCT/IB2012/000696 WO2012123823A1 (en) 2011-03-15 2012-03-12 Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2013010524A true MX2013010524A (en) 2013-12-06

Family

ID=46830101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010524A MX2013010524A (en) 2011-03-15 2012-03-12 Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.

Country Status (13)

Country Link
US (2) US9457045B2 (en)
EP (1) EP2685990A4 (en)
JP (1) JP2014509608A (en)
KR (1) KR20140038388A (en)
AU (1) AU2012228010B2 (en)
BR (1) BR112013023452A2 (en)
CA (1) CA2830195A1 (en)
IL (1) IL227719A0 (en)
MX (1) MX2013010524A (en)
RU (1) RU2013145869A (en)
SG (1) SG192957A1 (en)
WO (1) WO2012123823A1 (en)
ZA (1) ZA201307560B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US9457045B2 (en) 2011-03-15 2016-10-04 The University Of British Columbia Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
CN107428740A (en) * 2014-09-11 2017-12-01 埃萨内克斯股份有限公司 Indazolyl and indoles yl-benzamide derivatives
US11261187B2 (en) 2016-04-22 2022-03-01 Duke University Compounds and methods for targeting HSP90
WO2023023189A2 (en) * 2021-08-17 2023-02-23 University Of Virginia Patent Foundation Clusterin overexpression in alzheimer's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101052289B1 (en) 2002-08-21 2011-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 Treatment of melanoma with a decrease in the amount of cholesterol
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
PT1814595E (en) 2004-11-23 2014-04-02 Univ British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
CN101180275B (en) 2005-02-25 2014-09-10 瑟瑞耐克斯有限公司 Pyridine, and pyridazine derivatives
WO2006124904A2 (en) 2005-05-16 2006-11-23 Geron Corporation Cancer treatment by combined inhibition of telomerase and hsp90 activities
JP2013510585A (en) * 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド Compositions, kits and methods for cancer identification, evaluation, prevention and treatment
CA2830191A1 (en) 2011-03-14 2012-09-20 The University Of British Columiba Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
US9457045B2 (en) 2011-03-15 2016-10-04 The University Of British Columbia Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer
CA2836676A1 (en) 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
UY34812A (en) 2012-05-18 2013-12-31 Teva Pharma METHOD FOR TREATMENT OF LUNG CANCER OF NON-SMALL CELLS

Also Published As

Publication number Publication date
US20140080895A1 (en) 2014-03-20
RU2013145869A (en) 2015-04-20
JP2014509608A (en) 2014-04-21
CA2830195A1 (en) 2012-09-20
EP2685990A1 (en) 2014-01-22
US20170145418A1 (en) 2017-05-25
ZA201307560B (en) 2015-06-24
AU2012228010B2 (en) 2016-08-25
AU2012228010A1 (en) 2013-10-31
BR112013023452A2 (en) 2016-12-06
KR20140038388A (en) 2014-03-28
US9457045B2 (en) 2016-10-04
IL227719A0 (en) 2013-09-30
NZ616474A (en) 2015-06-26
EP2685990A4 (en) 2014-09-17
SG192957A1 (en) 2013-09-30
WO2012123823A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
MX2013010524A (en) Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2019010601A (en) Combination therapy for treating cancer.
MY183661A (en) Treatment of cancer with tor kinase inhibitors
UA115983C2 (en) Dna-pk inhibitors
WO2013030778A3 (en) Organic compositions to treat hsf1-related diseases
MY162903A (en) Methods of treatment of pancreatic cancer
MY162514A (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX363243B (en) Compositions and methods for treating cancer.
IN2012DN03883A (en)
MX2012007032A (en) Organic compositions to treat hsf1-related diseases.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2014002967A (en) Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells.
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
MX2013010530A (en) Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer.
MX340536B (en) Egfr targeted therapy.
MX2014003223A (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors.
MX2015012063A (en) Antisense oligonucletotides for treatment of cancer stem cells.
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
MX368261B (en) SYNTHETIC LETHALITY and THE TREATMENT OF CANCER.
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
WO2011128434A3 (en) Treatment of endocrine resistant breast cancer
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
WO2008067526A3 (en) Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers

Legal Events

Date Code Title Description
FA Abandonment or withdrawal